PeptideStack
5.2kquestions
20kanswers
220users

Why did my triglycerides move after ten weeks on cagrilintide?

Asked 25 Dec 2025Modified 6 months agoViewed 12k times
13

Setup, so nobody has to ask: triglycerides · ten weeks · cagrilintide.

Something has gone wrong and I would like to know how badly before I decide what to do.

Nothing else in the setup changed, which is what makes this puzzling.

What is the most likely explanation, and how would I confirm it?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
shareeditfollowflag
LB
askedlaminar_bench69k5725 Dec 2025
6Which analyte, and what reference interval did the laboratory print beside it? – lipid_panel_q 8 months ago
add a comment

3 Answers

Sorted by votes
10

10 weeks is 70 days, and the first question about any marker is whether 70 days is long enough for it to have finished moving. Triglycerides are the most volatile line on the panel: the fasting interval and the previous evening move them further than a month of treatment does. Against 70 days that puts the marker well inside its own settling time, so the value is reporting a new steady state rather than a transient. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 70 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Keep the full report, not the number. You will need the units and the interval later.

shareimprove this answerflag
HP
answeredh_pergande71k15821 Jan 2026
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
4

The short version: a small, well-chosen panel with a baseline beats a large one without.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

edited 18 Jan 2026 by lipid_panel_q — removed a claim I could not source

shareimprove this answerflag
LQ
answeredlipid_panel_q36k12730 Dec 2025
-2

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

shareimprove this answerflag
LQ
answeredlipid_panel_q36k12710 Jan 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.